Fox, K A A <br/><br/>
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?  [electronic resource] 

 -  European heart journal  05 2019 
 - 1466-1471 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1522-9645 
<br/><br/><label>Standard No.: </label>10.1093/eurheartj/ehy347  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aspirin--adverse effects<br/>Atherosclerosis--complications<br/>Chronic Disease<br/>Clinical Trials as Topic<br/>Death<br/>Drug Therapy, Combination<br/>Factor Xa Inhibitors--adverse effects<br/>Fibrinolytic Agents--adverse effects<br/>Hemorrhage--chemically induced<br/>Humans<br/>Myocardial Infarction--epidemiology<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Rivaroxaban--adverse effects<br/>Secondary Prevention--methods<br/>Stroke--epidemiology<br/>Thrombosis--prevention & control<br/>Vascular Diseases--pathology